Education and Innovation in Cardiovascular Medicine

Olive oil-supplemented Mediterranean diet can reverse metabolic syndrome

21-10-2014 • Babio N et al., CMAJ. 2014
Longer-term follow-up data suggest that a Mediterranean diet supplemented with extra-virgin olive oil is associated with reversal of metabolic syndrome, specifically regarding central obesity and high fasting plasma glucose. Read more
News • 21-10-2014

AHA Scientific Statement on CVD risk factors in the diabetic young

The American Heart Association has issued a scientific statement on management of cardiovascular disease (CVD) risk factors in young people with diabetes mellitus type 1 or 2. Read more

RCT refutes common believe that gradual weight loss has longer lasting effect than crash diet

20-10-2014 • Purcell et al., Lancet Diabetes & Endocrinology 2014
Regain of lost weight was similar in obese individuals randomised to a rapid or a gradual weight loss intervention. More participants in the rapid weight loss programme achieved weight loss of 12.5%. Read more
Webcast • Snapshot 2014

Is inflammation reduction key for targeting residual risk, beyond lowering LDL-c?

Dr. Paul Ridker, Boston, describes the different inflammatory pathways and ongoing clinical trials targeting inflammation Watch

GDF-15 levels may improve risk assessment for bleeding and mortality in AF

14-10-2014 • Wallentin L et al., Circulation. 2014
Growth differentiation factor 15, a marker of oxidative stress and inflammation, improves risk stratification for bleeding and mortality beyond clinical risk factors in anticoagulated patients with AF Read more

Effect of high-intensity statins on atherosclerosis does not depend on baseline lipid status

13-10-2014 • Puri R et al., Am J Cardiol. 2014
High-intensity statins attenuate coronary atherosclerosis irrespective of baseline levels of atherogenic or protective lipoproteins or CRP. Read more
News • 13-10-2014

An impression of the controversies and hot issues discussed at the PACE SNAPSHOT meeting

This meeting provided a comprehensive update of the latest developments and challenges in the managament of CVD. What follows is an impression of what was discussed. Read more
Webcast • Snapshot 2014

What do novel diabetes drugs add to CV risk reduction?

Prof. Naveed Sattar, Glasgow, UK provides his view on the potential role of novel diabetes drugs in CV risk management Watch

Amiodarone use together with warfarin increases risk of stroke/SE and lowers TTR

15-10-2014 • Flaker G et al., J Am Coll Cardiol. 2014
Substudy of ARISTOTLE shows that apixaban consistently reduced the rate of stroke and SE, death and major bleeding when compared with warfarin, whether patients received amiodarone or not. Read more

SGLT2 inhibition reduces blood pressure in patients with T2DM and hypertension

14-10-2014 • Tikkanen I et al., Diabetes Care. 2014
Phase III results show that 12 weeks of treatment with SGLT2 inhibitor empagliflozin safely improves blood pressure, and lowers HbA1c and body weight, in hypertensive T2DM patients. Read more
News • 13-10-2014

EMA’s PRAC: no increased risk of heart problems with testosterone medicines

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a review of testosterone-containing medicines following concerns over serious cardiovascular side effects. Read more

CETP inhibition with dalcetrapib differentially affects cholesterol absorption when ABCA1 or ApoA1 is mutated

7-10-2014 • Niesor EJ et al., Lipds Oct 2014
The ABCA1-ApoA1 axis appears central to the lipidation of nascent HDL and it contributes to the intestinal absorption of cholesterol and phytosterols. Read more